@mingmingin
Account based inJapan!
About this account
- Account based in
- Japan
- Connected via
- China Android App
X says this location may be affected by a proxy or VPN.
Account-level information from X, not a live location or the device used for a specific post.
View mine
Shanghai
Joined March 2020
- Tweets145
- Following374
- Followers60
- Likes129
Interesting
I wrote about the state of AI, why I’m concerned about the next few years, and the choices we need to make to keep the future in humanity’s hands.
An Alien Mind: openai.com/index/an-alien-mi…
first approved BCG+IO combination
FDA approves durvalumab in combination with BCG for high-risk non-muscle invasive #bladdercancer
@IBCG_BladderCA @DrFelixGuerrero @joanfundi @tompowles1 @AndreaNecchi @JoshMeeks #ASCO26
TaHG as High risk
Time to revisit something I’ve been saying for years: TaHG bladder cancer is not intermediate risk. The clinical outcomes, molecular biology ... all point in the same direction.
Yet some frameworks allow < 3cm TaHG tumors to be downgraded into “intermediate risk” alongside low-grade disease.
That classification has real consequences for patients:
• undertreatment
• less rigorous surveillance
• in some studies, these patients are even placed on observation as a supposedly appropriate “control arm.”
TaHG is high risk. 🧵 @BladderCancerUS @WorldBladderCan @IBCG_BladderCA
Marc Zhang retweeted
A common concern: reduced dose BCG = inferior outcomes.
The data do not support that. Across RCTs and real-world series, 1/3 dose BCG achieves comparable recurrence, progression, and survival outcomes.
Why? BCG is not a fixed-dose drug. Each vial has up to 10-fold variability in viable organisms (CFUs). "Dose" on paper does not reflect true biologic exposure. 🔬
"Full dose" from a low-CFU vial can deliver less BCG than "reduced dose" from a high-CFU vial.
#BladderCancer
Wish more patient could preserve their bladder.
Great article explaining an important issue. @BladderCancerUS we need advocacy on this issue. @bladd
statnews.com/2026/04/01/osto…
Rapamycin could reverse aging, after being anti-tumor and suppressing immune reactions in renal/other transplants.
Advance IR patient management and trial design
So exciting that this is now in the NCCN guidelines!
No doubt that this will better stratify IR NMIBC patients for clinical trials.
Grateful to @UroDocAsh and the @IBCG_BladderCA team for the opportunity to lead this work
pubmed.ncbi.nlm.nih.gov/3571…
Join and learn the latest update
Great initiative by the European Urology team!
A smart way to stay current with the latest across EU journals.
@EurUrolOpen @EurUrolOncol @EurUrolOncol @EUplatinum @Uroweb
A more common target in Ta intermediate-risk patients.
FGFR3 targeted therapy is going though a renaissance with blood based biomarkers, new agents such a Vepugratinib and novel delivery methods (moonrise program) @giannatempopatr @OncoAlert #GUtrendingtopics
The pembro+EV, PD-1+ADC combination shifts to bladder-sparing.
A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert
Marc Zhang retweeted
Thank you @crisbergerot! We are thrilled to be opening the #EMPOWER trial @uwurology @fredhutch *this week* after introducing our protocol at #ASCOGU2026 @HannaHunterMD @CindyLinMD
@ASCO #GU26 Poster M9: The EMPOWER Trial @spsutkaMD
A randomized study evaluating a home-based physical activity program via ExerciseRx™ vs health education in NMIBC
Targeting function, frailty, HRQoL, and treatment burden in an older, vulnerable population
Marc Zhang retweeted
#ASCOGU26
Congrats @MattGalsky on leading this novel ph 1 trial of FX-909, a 1st in class oral PPARγ inverse agonist in solid tumors including mUC.
PPARγ is a master regulator of luminal lineage & its activation drives tumorogenesis.
FX-909 shows promising efficacy in IHC selected tumors.
Key TRAEs anemia, hyperglycemia, fatigue. thrombocytopenia.
Provides rationale for dose expansion and combo studies.
Glad to be a part of this novel work.
@CleClinicMD
nature.com/articles/s41591-0…
FIH PPARG inverse agonist for luminal urothelial cancer rdcu.be/e5602 #GU26
@NatureMedicine @TischCancer @apolo_andrea @shilpaonc @BourlonMaite @PGrivasMDPhD @AmandaNizamMD @DrKarineTawagi @drenriquegrande @PGrivasMDPhD @urotoday
@Uromigos
@OncBrothers
@OncoAlert
Marc Zhang retweeted
Gemcitabine intravesical system in combination with cetrelimab vs chemoradiotherapy in #MIBC: #SunRISe-2 final results. Presented by @AndreaNecchi @MyUniSR. #GU26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3MOYthQ
Dr.Noah hahn For and Dr. Felix GR Against BCG+IO in BCG naive NMIBC，continue discussion from ESMO last year in several session.
KEYNOTE-B15 trial move MIBC to no cisplatin era after la/m BC. more 👏🏻👏🏻👏🏻interrupt Dr.Galsky presentation. #ASCOGU26
Marc Zhang retweeted
Nice progress on drugging p53. It’s true that we need to find new targets, but it’s also important to keep expanding the druggable universe with better technologies.
Lots of great targets we already know about that are just waiting for the right molecule
In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: nej.md/3OIQC5P
Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors nej.md/3N0pQW8
ALT Panel A: A figure showing the change in the sum of diameters of the target lesions across tumor types. Panel B: A figure showing the overall duration of treatment and the time to first response observed in 46 patients treated with a dose in the observed efficacious-dose range who had wild-type KRAS.
With ASCO GU 2026 upon us, oncologists are already weighing in, sharing, and debating the most anticipated genitourinary oncology abstracts ahead of the meeting.
We’re tracking these conversations in real time and analyzing what’s gaining traction across the community. Here are the pre-conference Top abstracts for ASCO GU 2026.
Special thanks to Dr. Mike Thompson (@mtmdphd) for the original idea.
Which abstract are you watching at American Society of Clinical Oncology (@ASCO) Genitourinary Cancers Symposium 2026?
Explore more insights and data from #GU26: bit.ly/3YGGH2w
#LARVOL #ASCOGU26 #CancerResearch #CancerData #Oncology #OncologyInsights #GUCancer #GenitourinaryCancer #GUCSM
Discussion threads:
Dr. Álvaro Pinto (@dralvaropinto): nitter.cf/dralvaropinto/status/2…
Dr. Amol Akhade (@SuyogCancer): nitter.cf/SuyogCancer/status/202…
Dr. Karine Tawagi (@DrKarineTawagi): nitter.cf/DrKarineTawagi/status/…
Dr. Mustafa J. Saleh (@Mustafajsalehmd): nitter.cf/Mustafajsalehmd/status…
Dr. Tom Powles (@tompowles1): nitter.cf/tompowles1/status/2013…
Dr. Toni Choueiri (@DrChoueiri): nitter.cf/DrChoueiri/status/2025…
